Retrospective 199 sarcoidosis patients showing non-statistically significant HCQ RR 0.83, p
Desbois et al., 7/20/2020, retrospective, France, Europe, preprint, mean age 58.8, 13 authors.
risk of COVID-19 case, 16.9% lower, RR 0.83, p = 1.00, treatment 3 of 27 (11.1%), control 23 of 172 (13.4%).
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.